Cage Pharma (2)

Executive Summary

Cage Pharma is a preclinical-stage biopharmaceutical company developing novel therapeutics targeting tumor metabolism, specifically glycolysis inhibition in cancer cells. Its lead compound, CP-102, is advancing toward a Phase 1 clinical study. The company is based in San Diego and was founded in 2018. As a private, early-stage company, Cage Pharma represents a high-risk, high-reward investment opportunity, with its success contingent on successful clinical development and potential differentiation in the competitive oncology landscape. The company has not disclosed funding or valuation details, and its profile completeness remains low, indicating limited public information. However, its focus on a validated but challenging target—cancer metabolism—positions it within a niche area of oncology that has attracted significant interest. The upcoming catalysts will be critical in assessing the drug's safety and initial efficacy signals.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for CP-10270% success
• Q4 2026Phase 1 Clinical Trial Initiation60% success
• 2027Initial Phase 1 Safety and PK Data40% success